Congratulations to The Engine on raising a $398 million third fund. Vaxess was honored to be mentioned as an Engine portfolio company in the recent Forbes feature about the news. "Vaxess, for example, is working on patches that deliver vaccines and biologics in a way that reduces the need for cold chains and syringes." https://lnkd.in/eQddsdky
Vaxess Technologies
Pharmaceutical Manufacturing
Boston, MA 8,207 followers
Engineering Immunity for All
About us
Vaxess Technologies is a venture capital and Gates Foundation-backed life science company developing novel vaccine formulations and delivery technologies based on its proprietary silk platform. We are committed to improving access to vaccines by enabling better, more stable vaccine products that can be easily delivered all over the world. Find more information at www.vaxess.com.
- Website
-
http://www.vaxess.com
External link for Vaxess Technologies
- Industry
- Pharmaceutical Manufacturing
- Company size
- 11-50 employees
- Headquarters
- Boston, MA
- Type
- Privately Held
- Founded
- 2012
- Specialties
- Vaccines and Pharmaceuticals
Locations
-
Primary
127 Western Avenue
Boston, MA 02134, US
Employees at Vaxess Technologies
Updates
-
We're hiring! Vaxess is looking for a scientist with biopharmaceutical experience to join our expanding team to bring innovative technology to the global therapeutica and vaccine market. If interested in joining the Vaxess team, please send your CV / resume to careers@vaxess.com or apply via the link below. We’re #hiring. Know anyone who might be interested?
-
Congratulations to the entire Vaxess team for the publication of our first phase 1 clinical trial results for the MIMIX skin patch for vaccines and therapeutics. This specific clinical trial evaluated the “safety, reactogenicity, tolerability and immunogenicity of H1N1 influenza vaccine delivered by VX-103 (a MIMIX microneedle patch [MAP] system) in healthy adults.” You can read the full paper below, which details the clinical trial’s success — namely, “the MIMIX MAP platform is safe, well tolerated and elicits robust antibody responses.” The Vaxess team looks forward to continuing to apply the MIMIX skin patch to a range of additional vaccines and therapeutics. https://lnkd.in/gJ98DawK
Phase 1, randomized, rater and participant blinded placebo-controlled study of the safety, reactogenicity, tolerability and immunogenicity of H1N1 influenza vaccine delivered by VX-103 (a MIMIX microneedle patch [MAP] system) in healthy adults - PubMed
pubmed.ncbi.nlm.nih.gov
-
Vaxess CEO, Rachel Sha, had the pleasure of meeting and learning from many of the amazing thought leaders and pioneers in the biotech space. Thanks to Biotechnology Innovation Organization for hosting another great convention this week!
CEO at Vaxess Technologies | Global Digital Life Sciences Executive | Entrepreneurial Leader | Digital Transformation | Deal Maker | Culture Change Advocate
What a jammed packed week @ Bio! Great to catch up with colleagues and meet new ones innovating in vaccines and GLP-1 spaces. Special thanks to BARDA BAN, BioLabs, Start2 Group, and Advise Connect Inspire, LLC for the opportunity to join the panel at the VITAL – A BARDA BAN Hub launch(Vaccine Innovation & Therapeutics Acceleration Launchpad). I really appreciated the nuggets of wisdom and advice from co-panelists, Johannes Fruehauf (Mission BioCapital), Mary Larkin (BARDA BAN), Saroj Regmi, PhD (NCI SBIR), and expertly moderated by Marc Filerman (Start2). This was the launch event for VITAL and was kicked off with energizing words from Dawn O'Connell (Assistant Secretary for Preparedness and Response) and Ashim Subedee (BARDA DRIVe). I had the pleasure of discussing Vaxess Technologies' efforts in this space, notably with our partners AstraZeneca in pandemic flu. Amazing to see the number of entrepreneurs, scientists, investors, and agencies supporting early stage innovation in this space.
-
Thank you to Pulse 2.0 for spreading the good news about our recent funding announcement! https://lnkd.in/eQDXCN6u
Vaxess: $12 Million Raised To Develop Shelf-Stable MIMIX Skin Patch For Vaccines And Therapeutics
https://pulse2.com
-
Thank you to Drug Delivery Business News for the feature on our recent funding announcement! Read the full article here: https://lnkd.in/dyu9ZG7v
Vaccine patch maker Vaxess raises $12M, names new CEO
https://www.drugdeliverybusiness.com
-
Thank you to Hannah Green at the Boston Business Journal for meeting with new Vaxess CEO, Rachel Sha, to learn more about the transition and the exciting plans she has in store for Vaxess. Read the full article here: https://lnkd.in/gpWwzBCp
Genzyme vet named to lead startup developing vaccines-in-a-patch - Boston Business Journal
bizjournals.com
-
Today, Vaxess is announcing $12M in additional funding for its industry-leading skin patch for drug delivery. We’re honored to be backed by an extraordinary team of investors in the vaccine and therapeutic space, including RA Capital Management, Engine Ventures, Global Health Investment Corporation, and Mission BioCapital. After a year where Vaxess has demonstrated feasibility of GLP-1 delivery, and partnered with leading biopharma companies in vaccines (mRNA and non-mRNA), Vaxess will focus on applying the MIMIX skin patch to a range of therapeutics and vaccines. With this additional funding, Vaxess is also announcing that Michael Schrader is stepping down as the company’s CEO, and Rachel Sha is joining the company as CEO. https://lnkd.in/e-UN-Hki
News – News: Vaxess Announces $12M in Funding | Vaxess
vaxess.com
-
See some thoughts below from Vaxess CEO Michael Schrader on the recent The Wall Street Journal article highlighting some interesting elements of the Vaccine startup funding space.
I wanted to share a couple of thoughts on today’s Wall Street Journal article, Vaccine Startups Navigate Tight Financing Market — https://lnkd.in/ekYEC9sw First, I’d like to thank The Wall Street Journal Venture Capital Reporter Brian Gormley for taking the time to speak with me, and highlighting Vaxess Technologies’s success in raising funding and forming valuable partnerships, such as one we recently announced with AstraZeneca. Second, I’m glad to see The Wall Street Journal shine a light on the recent Biotechnology Innovation Organization (BIO) report, The State of Innovation in Vaccines and Prophylactic Antibodies for Infectious Diseases, which highlights the need for more public and private investment in vaccine development. You can read the full report here — https://lnkd.in/eZdUqR-Y. For me, the most notable stat was that between 2013-2022, only 3.4% of venture capital raised by biopharmaceutical companies went to companies with “infectious disease vaccine programs.” Phyllis Arthur, Senior Vice President for Infectious Disease and Emerging Science Policy at BIO, sums up the need for more investment perfectly in the concluding paragraph of the press release announcing the report, saying, "Vaccines have led to a 100% reduction in the risk of death for a host of devastating diseases. Yet many common infections don't have any vaccines in clinical development. That needs to change. We need to pursue both scientific and policy changes that can help spur investment in these vital products.” At Vaxess, we’re humbled to be an example of a company that has successfully raised funding in this very competitive space, and our hope is that this report will spur discussion that will lead to more funding for vaccine development — both the vaccines themselves, and novel approaches to vaccine delivery. Not only is it a win for patients, but the payoff for investors has been very strong in recent years.
Vaccine Startups Navigate Tight Financing Market
wsj.com
-
Vaxess CEO and co-founder, Michael Schrader, attended the J.P. Morgan Healthcare conference earlier in January. Read below for his key takeaways from the week.
JPM 2024 was an adventure, with the majority of deal news centering around the antibody-drug conjugate (ADC) space. Impressive acquisitions of Ambrx, ImmunoGen, Inc., and Orum Therapeutics's ORM-6151 as well as a $5B+ deal between Merck and Daichi Sankyo headlined the news. Labiotech.eu wrote a great summary of the madness in the space in December. The irony? The first successful ADC clinical trial was conducted in 1983, 40 years ago! The concept was clever, took decades to refine, and appeared to finally hit its stride, hence the lemming effect. And what happened less than two weeks post-JPM? Gilead Sciences's lead ADC, Trodelvy, fails a Ph III trial. According to STAT, this "raised questions around ADC's". Seriously? After $20B+ in deals over a 3-4 month period? My takeaway? Breakthrough products take great science, patience, money (lots of it), and some good luck. Let big pharma chase the hype. We'll focus on launching game-changing products.
M&As: what's up with the ADC buying spree?
https://www.labiotech.eu